Tempus Completes Acquisition of Ambry Genetics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
TD Cowen Reinstates Tempus AI Inc (TEM) at Buy
February 5, 2025 7:00 AM ESTTD Cowen analyst Dan Brennan reinstates coverage on Tempus AI Inc (NASDAQ: TEM) with a Buy rating and a price target of $74.00.
The analyst comments "TEM closed its Ambry acquisition & we reinstate coverage with Buy. The deal affords TEM w/ a $300M+, profitable... More



